The Centers for Disease Control and Prevention today awarded $26 million in grants through 2020 to five academic medical centers conducting research to prevent healthcare-associated and antibiotic-resistant infections as part of the agency’s Prevention Epicenters Program. The recipients are: Chicago Prevention and Intervention Epicenter at Rush University and Cook County Health and Hospitals System; Duke University and the University of North Carolina; The Harvard Pilgrim Health Care and University of California, Irvine; The University of Pennsylvania; and Washington University School of Medicine in St. Louis and BJC Healthcare Prevention Epicenter. The funding is part of CDC’s Antibiotic Resistance Solutions initiative. The Chicago Epicenter also received $4.45 million from CDC’s Safety and Healthcare Evaluation and Research Development contract to develop and test regional approaches for preventing transmission of antibiotic-resistant germs between health care facilities. “For nearly two decades, the Epicenters have advanced the fight against healthcare-associated infections with practical clinical innovations that have saved lives,” said CDC Director Tom Frieden, M.D. “Antibiotic-resistant infections are on the rise, making this research even more critical today than ever.”

Related News Articles

Headline
Hospitals, health systems and other health care organizations can sign up this week to host an intern for this year's Institute for Diversity and Health Equity…
Headline
The Centers for Disease Control and the National Tuberculosis Controllers Association this week released updated recommendations for TB screening and testing…
Headline
The House Ways and Means Committee today held a hearing examining the impact of racial disparities and social determinants of health on maternal mortality.
Headline
The Centers for Medicare…
Headline
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…